Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma

Histone deacetylases (HDACs) represent novel molecular targets for the treatment of various types of cancers, including multiple myeloma (MM). Many HDAC inhibitors have already shown remarkable anti-tumor activities in the preclinical setting; however, their clinical utility is limited due to unfavo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Minami, Jiro, Suzuki, Rikio, Mazitschek, Ralph, Gorgun, Gullu, Ghosh, Balaram, Cirstea, Diana, Hu, Yiguo, Mimura, Naoya, Ohguchi, Hiroto, Cottini, Francesca, Jakubikova, Jana, Munshi, Nikhil C., Haggarty, Stephen J., Richardson, Paul G., Hideshima, Teru, Anderson, Kenneth C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4165599/
https://ncbi.nlm.nih.gov/pubmed/23913134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.231
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge